Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma.

ABSTRACT:

SUBMITTER: Lamarca A 

PROVIDER: S-EPMC10651450 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature